Skip to main content
Funded Studies

James Lillie, PhD

Chief Scientific Officer at MapLight Therapeutics

Location: San Francisco, CA United States

James Lillie is the Chief Scientific Officer at MapLight Therapeutics. He has more than 25 years of experience driving preclinical research and development across diverse therapeutic areas and indications. Previously, he served as the Chief Scientific Officer at OvaScience. As Vice President of In Vitro Biology at Sanofi Genzyme, he was responsible for developing a scientific strategy to create a high-value portfolio of treatments for rare diseases. He established a strong pipeline of small molecule drugs and supported the U.S. Food and Drug Administration’s approval of Eliglustat and acceptance of two investigational new drug (IND) applications. Dr. Lillie holds a doctorate from Harvard University in biochemistry.

Associated Grants

  • Pre-clinical Validation of a Novel Target for Dyskinesia Induced by Levodopa


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.